27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Michael King, of JMP Securities, and Les Funtleyder, of E Squared Capital, were on CNBC Thursday discussing M&A activity in the biotech sector.
The Sanofi-Medivation Deal
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Talking about Sanofi SA (ADR) (NYSE: SNY)’s offer for Medivation Inc (NASDAQ: MDVN), King said he believes the latter will be acquired. It’s only “a matter of time and price,” he stated. “If Sanofi is serious, I think they should raise their bid,” he added. According to JMP’s research, Medivation could justify a valuation of more than $70 per share – well above the current $59.80, just based on its lead, prostate cancer drug, Xtandi. In addition, the company counts on a “wonderful pipline,” he assured. So, a higher bid should come, the expert concluded.
Merck Also Looking Into M&A
On Thursday morning, Merck & Co., Inc. (NYSE: MRK)’s CEO said the company is looking for more deals to expand its pipeline, rather than consolidation deals – although they would be open to a large one.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
While Funtleyder did not directly comment on these words, he did say he believes late stage assets are more likely to be acquired than early stage ones. This is why E Squared Capital has been looking into the biotech sector, seeking for attractive late stage companies – without clinical trial risk – that could be bought out. However, he added, the medical devices industry is more likely to post strong performance than the biotech sector.
The Sector In General
Will M&A help the biotech sector get out of “its funk?” Power Lunch’s anchor asked.
“I sure hope so,” King responded. “I think there is enough organic growth and enough breakthrough science for the sector to lift itself.”
The investor pointed out that large cap stocks are currently trading close to historic lows, in terms of valuation. This makes them relatively alluring on a valuation basis, he replied.
King went on to explain, “The one dysfunction between the desire and actual realization of M&A is the bull market of 2013–2015, where managements and boards saw their stocks at $40, $50 a share.” However, the stocks are now trading at single-digits, and nobody is willing to pay even $20 per share, he concluded. “So, that’s the real sticking point in M&A.”
Funtleyder concluded – and King agreed, stating he thinks companies want to be friendly in the M&A space, and that “they’ll be an increase in deal activity after the election.”
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.